Trial intelligence / Profile preview

Sorafenib plus capecitabine in advanced pre-treated colorectal cancer

2010-023695-91Phase 2Completed

Sponsor: Institut Jules Bordet
Start: Nov 2010
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of sorafenib and capecitabine in colorectal cancer (CRC), sponsored by Institut Jules Bordet. Primary endpoint: Overall survival at 6 months. Started Nov 2010; status: completed.

Drugs

sorafenibcapecitabine

Conditions

colorectal cancer (CRC)

Beyond the preview

Go deeper on 2010-023695-91.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-023695-91.